日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

MRTX1719 是一种 MTA 协同 PRMT5 抑制剂,在 MTAP 缺失型癌症的临床前模型和患者中表现出合成致死性。

Lars D Engstrom ,Ruth Aranda ,Laura Waters ,Krystal Moya ,Vickie Bowcut ,Laura Vegar ,David Trinh ,Allan Hebbert ,Christopher R Smith ,Svitlana Kulyk ,J David Lawson ,Leo He ,Laura D Hover ,Julio Fernandez-Banet ,Jill Hallin ,Darin Vanderpool ,David M Briere ,Alice Blaj ,Matthew A Marx ,Jordi Rodon ,Michael Offin ,Kathryn C Arbour ,Melissa L Johnson ,David J Kwiatkowski ,Pasi A Jänne ,Candace L Haddox ,Kyriakos P Papadopoulos ,Jason T Henry ,Konstantinos Leventakos ,James G Christensen ,Ronald Shazer ,Peter Olson

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

MRTX-500 II期试验:Sitravatinib联合Nivolumab治疗接受或正在接受免疫检查点抑制剂治疗或化疗后进展的非鳞状非小细胞肺癌患者

He, Kai; Berz, David; Gadgeel, Shirish M; Iams, Wade T; Bruno, Debora S; Blakely, Collin M; Spira, Alexander I; Patel, Manish R; Waterhouse, David M; Richards, Donald A; Pham, Anthony; Jotte, Robert; Hong, David S; Garon, Edward B; Traynor, Anne; Olson, Peter; Latven, Lisa; Yan, Xiaohong; Shazer, Ronald; Leal, Ticiana A

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy

一项针对接受抗血管生成治疗后病情进展的透明细胞肾细胞癌患者的西曲伐替尼联合纳武利尤单抗的1/2期临床试验

Msaouel, Pavlos; Goswami, Sangeeta; Thall, Peter F; Wang, Xuemei; Yuan, Ying; Jonasch, Eric; Gao, Jianjun; Campbell, Matthew T; Shah, Amishi Yogesh; Corn, Paul Gettys; Tam, Alda L; Ahrar, Kamran; Rao, Priya; Sircar, Kanishka; Cohen, Lorenzo; Basu, Sreyashi; Duan, Fei; Jindal, Sonali; Zhang, Yuwei; Chen, Hong; Yadav, Shalini S; Shazer, Ronald; Der-Torossian, Hirak; Allison, James P; Sharma, Padmanee; Tannir, Nizar M

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

术前使用西曲伐替尼和纳武利尤单抗治疗口腔癌的抗肿瘤免疫效应:SNOW 机会窗口研究

Oliva, Marc; Chepeha, Douglas; Araujo, Daniel V; Diaz-Mejia, J Javier; Olson, Peter; Prawira, Amy; Spreafico, Anna; Bratman, Scott V; Shek, Tina; de Almeida, John; R Hansen, Aaron; Hope, Andrew; Goldstein, David; Weinreb, Ilan; Smith, Stephen; Perez-Ordoñez, Bayardo; Irish, Jonathan; Torti, Dax; Bruce, Jeffrey P; Wang, Ben X; Fortuna, Anthony; Pugh, Trevor J; Der-Torossian, Hirak; Shazer, Ronald; Attanasio, Nickolas; Au, Qingyan; Tin, Antony; Feeney, Jordan; Sethi, Himanshu; Aleshin, Alexey; Chen, Isan; Siu, Lillian

Metagenomics of pasteurized and unpasteurized gouda cheese using targeted 16S rDNA sequencing

利用靶向16S rDNA测序对巴氏杀菌和未巴氏杀菌的豪达奶酪进行宏基因组学分析

Salazar, Joelle K; Carstens, Christina K; Ramachandran, Padmini; Shazer, Arlette G; Narula, Sartaj S; Reed, Elizabeth; Ottesen, Andrea; Schill, Kristin M

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

抗5T4抗体-单甲基澳瑞他汀偶联物PF-06263507在晚期实体瘤患者中的首次人体试验

Shapiro, Geoffrey I; Vaishampayan, Ulka N; LoRusso, Patricia; Barton, Jeremy; Hua, Steven; Reich, Steven D; Shazer, Ronald; Taylor, Carrie T; Xuan, Dawei; Borghaei, Hossein